Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In December 2019, a cluster of pneumonia cases of unidentified cause emerged in Wuhan,was identified as the culprit of this disease currently being identified as "Coronavirus Disease 2019" (COVID-19) by World Health Organization. Coronavirus was found to not only target the patient's lungs but also multiple organs. Around 2-33% of Coronavirus Disease-19 patients developed gastrointestinal symptoms. Studies have shown that Severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) was found in patient's feces, suggesting that the virus can spread through feces. In our previous study, stool samples from 15 patients with COVID-19 were analysed. Depleted symbionts and gut dysbiosis were noted even after patients were detected negative of SARS-CoV-2. A series of microbiota were correlated inversely with the disease severity and virus load. Gut microbiota could play a role in modulating host immune response and potentially influence disease severity and outcomes. The investigators are uncertain about the impact of synbiotic on patients with COVID-19. However, a therapeutic strategy aiming at investigating the gut Imicrobiota of patients with COVID-9 who take synbiotic or not, leading to lesser progression to severe disease, less hospital stay and improved quality of life.
Description: Combined symptom score improvement of the first 4 weeks. Symptoms score assessment ranges from 20-80. The higher the score, the worse the symptoms.
Measure: Combined symptom score Time: 4 weeksDescription: Compare the number and severity of symptoms existing by checking the list in symptoms assessment such as cough, shortness of breath, fever and gastrointestinal symptoms like anorexia, nausea, vomiting, abdominal pain, bloating before and during the study
Measure: Clinical improvement Time: 4 weeksDescription: Compare the time to develop antibody against SARS-CoV-2 in both group
Measure: Time to develop antibody against SARS-CoV-2 Time: 16 daysDescription: Improvement of quality of life measured by EQ-5D-5L. EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.The index can be calculated by deducting the appropriate weights from 1, the value for full health (i.e. state 11111). Each category ranges from 1 to 5. The small the number, the better the health. The EQ-VAS is a vertical visual analogue scale that ranges 0-100 (higher score indicates better imaginable health).
Measure: Quality of life measured by EQ-5D-5L Time: 4 weeksDescription: Improvement of quality of life measured by SF-12. SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. There are formulas for transformation of scale scores so that they will range from 0-100. High score in functioning items indicates better functioning while high score in pain items indicates freedom from pain.
Measure: Quality of life measured by SF-12 Time: 4 weeksDescription: Measure the duration of hospital stay in both group
Measure: Duration of hospital stay Time: up to 3 monthsDescription: Compare the time to negative PCR in both group
Measure: Time to negative PCR Time: through study completion, an average of 1 yearDescription: Trend of symptom score, ranges from 26-104. The higher the score, the worse the symptoms.
Measure: Trend of symptom score Time: 4 weeksDescription: Duration of gastrointestinal symptoms such as anorexia, nausea, vomiting, abdominal pain, bloating within 4 week.
Measure: Gastrointestinal symptoms Time: 4 weeksDescription: Changes in fecal bacteria metabolites measured by PCR at different time points
Measure: Changes in fecal bacteria metabolites Time: weeks 2, 4, 5 and 8 months 3, 6, 9 and 12Description: Change in plasma cytokines level at week 2 and week 5 compared with baseline
Measure: Change in plasma cytokines level Time: week 2 and week 5Description: Changes in the gut microbiome (bacteria, virome and fungome) measured by metagenomics at different time points (weeks 1, 2, 3, 4, 5 and months 3, 6, 9 and 12) compared to baseline
Measure: Changes in the gut microbiome Time: weeks 1, 2, 3, 4, 5, 8 and months 3, 6, 9 and 12Description: Number of admission to Intensive Care Unit
Measure: Number of admission to Intensive Care Unit Time: 4 weeksDescription: Number of subjects with home discharge
Measure: Number of subjects with home discharge Time: 4 weeksDescription: Number of mortality
Measure: Number of mortality Time: 4 weeksDescription: Number of days absent from work since admission
Measure: Number of days absent from work Time: 3 monthsDescription: Change in score on Quality of life using EQ-5D-5L and SF-12. EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.The index can be calculated by deducting the appropriate weights from 1, the value for full health (i.e. state 11111). Each category ranges from 1 to 5. The small the number, the better the health. The EQ-VAS is a vertical visual analogue scale that ranges 0-100 (higher score indicates better imaginable health). While the SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. There are formulas for transformation of scale scores so that they will range from 0-100. High score in functioning items indicates better functioning while high score in pain items indicates freedom from pain.
Measure: Change of quality of life questionnaire Time: week 8, months 3, 6, 9 and 12Description: Number of adverse event
Measure: Number of adverse event Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports